EMA Authorised: Vafseo (vadadustat) — Medice Arzneimittel Pütter GmbH & Co. KG

View source ↗

Summary

The EMA authorised vadadustat (brand Vafseo) for the treatment of anemia associated with chronic kidney disease in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• VAFSEO (VADADUSTAT)

Snippet

Status: Authorised. Therapeutic area: Renal Insufficiency, Chronic;Anemia. MAH: Medice Arzneimittel Pütter GmbH & Co. KG. Decision date: 24/03/2026